Approved indications: Pitavastatin calcium is FDA-approved as an adjunct to diet to reduce low-density lipoprotein (LDL) cholesterol in adults with primary hyperlipidemia and in adults and children 8 years and older with heterozygous familial hypercholesterolemia.

Off-label uses (clinician-directed):

• Treatment of mixed dyslipidemia or elevated non-HDL cholesterol when a moderate-intensity statin is appropriate.
• Management of dyslipidemia in people who are intolerant of or have drug–drug interactions with other statins, including some patients with diabetes or metabolic syndrome.
• Use in certain complex patients (for example, with HIV or on multiple other medications) where its relatively low potential for CYP450 drug interactions is advantageous; evidence is mainly from smaller trials and observational studies.

Efficacy expectations:

• At usual doses of 2–4 mg once daily, pitavastatin typically lowers LDL cholesterol by roughly 30–45% and also improves triglycerides and HDL cholesterol, with near-maximal effect seen in about 4 weeks.
• Cholesterol levels often begin to improve within 1–2 weeks, and most patients who respond maintain reductions with long-term daily use.
• Its LDL-lowering effect at 2–4 mg is comparable to other moderate-intensity statins; like the class, it is expected to reduce cardiovascular risk when LDL is lowered, though large dedicated outcome trials for pitavastatin are fewer than for atorvastatin or rosuvastatin.

Typical adult and pediatric dosing (oral): For adults and children 8 years and older with high LDL cholesterol, the usual dose is 2–4 mg by mouth once daily, with a maximum of 4 mg per day; your prescriber may start at 2 mg and adjust the dose after about 4 weeks based on cholesterol levels and tolerability.

Kidney and other dose adjustments: In people with moderate or severe kidney impairment or end-stage kidney disease on hemodialysis, the recommended starting dose is 1 mg once daily, and the maximum dose is 2 mg once daily. Dose limits also apply with certain interacting medicines (for example, not more than 1 mg daily with erythromycin and not more than 2 mg daily with rifampin), and pitavastatin must not be used with cyclosporine.

How to take the medicine:

• Take pitavastatin calcium by mouth once a day, with or without food, at about the same time each day.
• Swallow the tablet whole with water; do not crush, chew, or split unless your pharmacist specifically confirms it is safe.
• Continue following a heart-healthy diet and lifestyle, since the medicine works best together with diet, exercise, and weight control.

Special dosing instructions: Your clinician will periodically check your cholesterol (often about 4–12 weeks after starting or changing the dose) and may adjust the dose or switch to another statin if LDL goals are not reached with 4 mg or if side effects occur. Tell your prescriber about all other medicines you take so that pitavastatin dosing can be adjusted if needed.

Missed dose: If you miss a dose, take it as soon as you remember the same day; if it is almost time for your next dose, skip the missed dose and resume your regular schedule, and do not take two doses at once.

Overdose: If too many tablets are taken, contact a poison control center (in the U.S., 1-800-222-1222) or seek emergency medical care right away; there is no specific antidote, and treatment usually focuses on monitoring and managing symptoms such as severe muscle pain or dark urine.

Common side effects (usually mild):

• Muscle aches or cramps (myalgia), back pain, or pain in the arms or legs.
• Constipation, diarrhea, or stomach discomfort.
• Headache, flu-like symptoms, or mild throat or nasal symptoms (such as nasopharyngitis).
• Most occur in a small percentage of patients, are dose-related, and often improve with dose adjustment or switching statins.

Serious or rare adverse effects (seek immediate care):

• Signs of severe muscle injury or rhabdomyolysis: intense muscle pain or weakness, dark or cola-colored urine, fever, or extreme fatigue.
• Signs of liver injury: unusual fatigue, loss of appetite, upper right abdominal pain, dark urine, or yellowing of the skin or eyes.
• Allergic reactions: rash, itching, hives, swelling of the face, lips, tongue, or throat, or trouble breathing.

Warnings and precautions: Do not use pitavastatin calcium in people with active liver disease, unexplained persistent elevation of liver enzymes, known hypersensitivity to pitavastatin, or in combination with cyclosporine. It is generally avoided during pregnancy because lowering cholesterol is not usually needed and fetal risk is possible, and it should not be used while breastfeeding since statins can pass into breast milk. Extra caution and lower starting doses are used in older adults, people with moderate to severe kidney impairment or on hemodialysis, those with untreated hypothyroidism, or a history of statin-related muscle problems.

Overall safety profile: Overall, pitavastatin has a safety profile similar to other moderate-intensity statins, with low rates of serious muscle or liver injury when used at recommended doses. Data suggest it has neutral or possibly favorable effects on blood sugar compared with some other statins, but, as with the class, small increases in blood sugar can occur in some patients.

Reporting side effects and safety updates: Side effects should be reported to a healthcare professional and can also be reported directly to the FDA MedWatch program (online or by calling 1-800-FDA-1088), and up-to-date safety communications are available on the FDA’s website.

Major prescription drug interactions:

• Cyclosporine: Contraindicated; greatly increases pitavastatin levels and risk of serious muscle injury.
• Erythromycin: Raises pitavastatin levels; the pitavastatin dose should not exceed 1 mg once daily when used together.
• Rifampin: Increases pitavastatin exposure; the pitavastatin dose should not exceed 2 mg once daily.
• HIV and hepatitis C protease inhibitors (for example, atazanavir, lopinavir/ritonavir, darunavir/ritonavir): Can change pitavastatin levels and may require dose adjustment or choosing an alternative statin.
• Gemfibrozil and other fibrates, high-dose niacin, colchicine: Increase the risk of muscle problems when combined with pitavastatin; these combinations require caution and close monitoring or avoidance.
• Certain antifungals (such as itraconazole) and other interacting drugs: May alter pitavastatin levels and call for careful review of doses.

OTC medicines and supplements: High-dose niacin products, some fiber or bile-acid-binding agents, and “red yeast rice” (which contains statin-like compounds) can add to cholesterol-lowering or muscle side effects; always check with a clinician or pharmacist before combining them with pitavastatin.

Food, alcohol, and lifestyle:

• Grapefruit juice causes only small changes in pitavastatin levels compared with some other statins, but very large or frequent amounts are best avoided.
• Limit alcohol intake because both alcohol and statins can affect the liver, and heavy drinking is discouraged.
• Maintain a low-cholesterol, heart-healthy diet and regular physical activity to maximize benefit.

Conditions and co-medications requiring caution or avoidance:

• Active liver disease, decompensated cirrhosis, or persistent unexplained liver enzyme elevations (do not use).
• History of statin-associated muscle disease, untreated hypothyroidism, severe kidney impairment, or heavy alcohol use (use lower doses and close monitoring).
• Pregnancy and breastfeeding (generally avoid), and children under 8 years of age (not approved).

Monitoring needs:

• Fasting lipid panel at baseline and about 4–12 weeks after starting or changing the dose, then periodically to ensure cholesterol goals are met.
• Liver enzyme tests at baseline and as clinically indicated, especially if symptoms of liver injury appear.
• Creatine kinase (CK) levels if significant muscle pain, tenderness, or weakness develops.
• Kidney function tests in people with known kidney disease or at risk for kidney problems.
• If taken with warfarin or other blood thinners, monitoring of INR or other clotting tests when pitavastatin is started or stopped.

Q: How long does pitavastatin calcium take to start lowering my cholesterol?
A: Cholesterol levels usually begin to improve within 1–2 weeks, with full effect seen in about 4 weeks, which is why blood tests are often repeated 4–12 weeks after starting or changing the dose.

Q: Will I need to take pitavastatin calcium for the rest of my life?
A: High cholesterol is typically a long-term condition, so pitavastatin is often taken indefinitely unless lifestyle changes, other treatments, side effects, or new health issues lead your clinician to adjust or stop therapy.

Q: What should I do if I develop muscle pain while taking pitavastatin?
A: Mild soreness can occur, but if you notice persistent or worsening muscle pain, weakness, or cramps—especially with dark urine or fever—contact your healthcare professional promptly to decide whether to stop the medicine and do blood tests.

Q: Can I drink alcohol while taking pitavastatin calcium?
A: Light to moderate alcohol use is generally acceptable if you do not have liver disease, but heavy drinking increases the risk of liver problems and should be avoided while taking a statin.

Q: Do I need to avoid grapefruit juice with pitavastatin?
A: Pitavastatin is less affected by grapefruit juice than some other statins, so small amounts are usually acceptable, but it is still wise to avoid very large or frequent amounts unless your clinician says otherwise.

Storage: Store pitavastatin calcium tablets at room temperature (about 68–77°F / 20–25°C) in a tightly closed original container, protected from moisture, heat, and light, and keep them out of reach of children and pets.

Handling: Keep tablets dry, do not store them in the bathroom, and do not use tablets that are chipped, discolored, or past the expiration date.

Disposal: When the medicine is no longer needed, use a drug take-back program if available; if not, mix unused tablets with an unappealing substance (such as coffee grounds or cat litter), seal in a bag or container, and place in household trash, and do not flush tablets down the toilet unless specifically instructed.